| A Study to Evaluate Safety of ASC40 Tablets in Patients With Moderate to Severe Acne Vulgaris (NCT06248008) | Ascletis Pharmaceuticals Co., Ltd. | 2024-04-18 |
| A Study to Evaluate the Safety and Efficacy of ASC40 (Denifanstat) Tablets in the Treatment of Patients With Moderate to Severe Acne Vulgaris (NCT06192264) | Ascletis Pharmaceuticals Co., Ltd. | 2024-01-23 |
| Study to Evaluate Safety, Tolerability, PK and the Food Effect on PK of ASC11/RTV Tablets in Healthy Subjects (NCT05718518) | Ascletis Pharmaceuticals Co., Ltd. | 2023-01-13 |
| Study to Evaluate Safety, Tolerability, Efficacy and Pharmacokinetics of ASC10 in Mild to Moderate COVID-19 Patients (NCT05596045) | Ascletis Pharmaceuticals Co., Ltd. | 2022-11-28 |
| Study to Evaluate Safety, Tolerability, Pharmacokinetics and the Food Effect on PK of ASC10 Tablets in Healthy Subjects (NCT05523141) | Ascletis Pharmaceuticals Co., Ltd. | 2022-10-07 |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61in Subjects With Advanced Solid Tumors (NCT05287399) | Ascletis Pharmaceuticals Co., Ltd. | 2022-08-02 |
| Study to Evaluate Safety, Tolerance and Efficacy of ASC22 Combined With ART in Subjects With HIV (NCT05330143) | Ascletis Pharmaceuticals Co., Ltd. | 2022-06-28 |
| Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM (NCT05118776) | Ascletis Pharmaceuticals Co., Ltd. | 2022-01-21 |
| Study to Evaluate the Safety and Efficacy of ASC40 in Subjects With Moderate to Severe Acne Vulgaris (NCT05104125) | Ascletis Pharmaceuticals Co., Ltd. | 2022-01-12 |
| Study to Evaluate Safety and Efficacy of ASC42 Combined With ETV and PEG-IFN α-2a in Subjects With HBV (NCT05107778) | Ascletis Pharmaceuticals Co., Ltd. | 2022-01-10 |
| Study to Evaluate Safety, Tolerability and Pharmacokinetics of ASC42 in Chinese Healthy Subjects (NCT04965337) | Ascletis Pharmaceuticals Co., Ltd. | 2021-07-11 |
| Study to Evaluate the Effects of Itraconazole and Rifampin on the Pharmacokinetics of ASC40 in Healthy Subjects (NCT04843449) | Ascletis Pharmaceuticals Co., Ltd. | 2021-04-04 |
| A Study of the Pharmacokinetics of ASC09F in Healthy Subjects (NCT04547894) | Ascletis Pharmaceuticals Co., Ltd. | 2020-11-09 |
| A Study of the Relative Bioavailability of ASC41 in Healthy Subjects (NCT04527250) | Ascletis Pharmaceuticals Co., Ltd. | 2020-09-16 |
| A Phase II Study of Subcutaneously Injected PD-L1 Antibody ASC22 in Chronic Hepatitis B Patients (NCT04465890) | Ascletis Pharmaceuticals Co., Ltd. | 2020-07-17 |
| Ascending Single-dose Study to Evaluate TVB-2640 in Chinese Healthy Subjects (NCT04352361) | Ascletis Pharmaceuticals Co., Ltd. | 2020-04-02 |
| A Study of the Relative Bioavailability of ASC18 Tablets vs Reference Tablets in Healthy Volunteers (NCT04358523) | Ascletis Pharmaceuticals Co., Ltd. | 2020-03-20 |
| A Study to Evaluate the Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China (NCT03430830) | Ascletis Pharmaceuticals Co., Ltd. | 2018-01-15 |